The Story of Successful Drugs and Recent FDA-Approved Molecules

A topical collection in Pharmaceuticals (ISSN 1424-8247). This collection belongs to the section "Medicinal Chemistry".

Viewed by 673

Editors


E-Mail Website1 Website2
Collection Editor
1. Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Porto, Portugal
2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Interests: medicinal chemistry; organic synthesis; heterocycles; P-glycoprotein; anticancer; antimicrobials; chiral drugs; marine natural products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Collection Editor
Formerly Head, Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
Interests: heterocycles; medicinal chemistry; green chemistry; microwave-induced synthesis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Collection Editor

E-Mail Website
Collection Editor
PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149 Muenster, Germany
Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Each year, the FDA approves dozens of novel small molecules and biological derivatives as new therapeutic compounds, thus demonstrating the vigor of the pharmaceutical industry and associated research groups. Small molecules are the most represented entities among the approvals, but there are also an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases and rare diseases.

We invite readers of this Topical Collection to explore a range of short but comprehensive and updated reviews on drugs attracting particular attention owing to their success and to their compounds being (recently) approved by the FDA.

Dr. Maria Emília De Sousa
Dr. Jean Jacques Vanden Eynde
Prof. Dr. Klaus Kopka
Dr. Annie Mayence
Prof. Dr. Joachim Jose
Prof. Dr. Guangshun Wang
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • aptamer
  • oligonucleotide
  • orphan disease
  • orphan drug
  • peptide
  • small molecule

Published Papers (1 paper)

2024

21 pages, 6319 KiB  
Article
Remapping the Chemical Space and the Pharmacological Space of Drugs: What Can We Expect from the Road Ahead?
by Lucas Silva Franco, Bárbara da Silva Mascarenhas de Jesus, Pedro de Sena Murteira Pinheiro and Carlos Alberto Manssour Fraga
Pharmaceuticals 2024, 17(6), 742; https://0-doi-org.brum.beds.ac.uk/10.3390/ph17060742 - 6 Jun 2024
Viewed by 374
Abstract
This work examines the current landscape of drug discovery and development, with a particular focus on the chemical and pharmacological spaces. It emphasizes the importance of understanding these spaces to anticipate future trends in drug discovery. The use of cheminformatics and data analysis [...] Read more.
This work examines the current landscape of drug discovery and development, with a particular focus on the chemical and pharmacological spaces. It emphasizes the importance of understanding these spaces to anticipate future trends in drug discovery. The use of cheminformatics and data analysis enabled in silico exploration of these spaces, allowing a perspective of drugs, approved drugs after 2020, and clinical candidates, which were extracted from the newly released ChEMBL34 (March 2024). This perspective on chemical and pharmacological spaces enables the identification of trends and areas to be occupied, thereby creating opportunities for more effective and targeted drug discovery and development strategies in the future. Full article
Show Figures

Figure 1

Back to TopTop